A new automated diagnostic test can quickly and accurately identify most leading causes of Gram-positive bacterial blood stream infections and the presence of three antibiotic resistance genes, according to a new study published this week in PLOS Medicine.
Neurodegenerative diseases such as Alzheimer's could be better understood thanks to insight into proteins linked to such conditions, a study suggests. Scientists studying thread-like chains of protein have found that low levels of these proteins may cause more harm to health than high levels.
The introduction of CT pulmonary angiography has been associated with an 80% rise in the detection of pulmonary emboli in the US, but with little change in death rates. Professor Renda Soylemez Wiener and colleagues argue this is evidence of overdiagnosis.
Older adults diagnosed with brain disorders such as Parkinson’s disease often feel a loss of independence because of their lack of mobility and difficulty walking. To better understand and improve these mobility issues, a research team is working toward building a more advanced motion test.
In new research, Hao Yan and his colleagues at Arizona State University's Biodesign Institute describe a pair of tweezers shrunk down to an astonishingly tiny scale. When the jaws of these tools are in the open position, the distance between the two arms is about 16 nanometers.
Early-stage MitrAssist whizzed by it's hoped-for raise of $600,000, landing $1 million from angel and private investors in support of the company's mitral valve implant. MitrAssist, a spin-out of Tredline Group's accelerator program, is developing what it calls a "valve-on-valve" approach to treat mitral regurgitation for patients too elderly or unstable for an invasive open-heart operation.
New York-based lifesciences investment group Iguana Healthcare Partners filed an amended notice, reporting that the company has raised more than $53.5 million in pooled investment fund interests. The funding, raised among 20 unnamed investors, will support Iguana's interests in pharmaceuticals, biotechnology, medical devices, diagnostics, healthcare services and healthcare information technology.
One of the greatest pleasures I have as FDA commissioner is the opportunity to meet with so many who are making a real difference in the world of health care, including researchers, doctors, drug industry leaders, foundations, and advocates for patients and families, including most recently the Alexandria Summit for Oncology.
Guided Therapeutics Continues to Await Update from FDA on Its PMA Application for LuViva® Advanced Cervical ScanJuly 3, 2013 8:06 am | by Business Wire | Comments
Guided Therapeutics commented on the status of its Pre-market Approval application for the LuViva Advanced Cervical Scan. While the Company requested a phone meeting with the FDA after the passing of their 180 day internal guidance and did speak with the agency, the company was informed that LuViva remains under FDA review.
Blaze Biosciences is more than halfway to a targeted $15 million in a Series B round to fund its Tumor Paint, a surgical tool that visually distinguishes solid tumor cells from healthy cells. Founded in 2010, the Seattle, Wash.-based Blaze Biosciences has roped in about $8.1 million since opening the round in June.
Under fire for being too lenient with medical device approvals, European regulators proposed an update to current CE Mark review and approval practices. Specifically, the European Commission's proposed changes address the relative ease with which companies can secure CE Mark approval by "shopping" for an agency in a specific country that will most quickly green-light a new device.
Retina Implant AG, the leading developer of subretinal implants for patients blinded by retinitis pigmentosa, today announced that its wireless subretinal implant technology, the Alpha IMS, has received CE Mark. Retina Implant's technology, which has been in clinical trials across the world since 2005, is designed to restore useful vision in patients blinded by the degenerative eye condition retinitis pigmentosa.
ArthroCare (NSDQ:ARTC) said it closed its $45 million acquisition of ENTrigue Surgical and bought a nearly 20% stake in Israeli medical device company Ortho-Space. The deal price for ENTrigue, which makes a device to treat chronic sinusitis, includes "contingent consideration" pegged to sales growth milestones, according to a press release.
Dialysis technology makers slid hard today after the Center for Medicare & Medicaid Services proposed a reimbursement decrease of more than 9% for 2014. As of about 2:45 p.m. DaVita Inc. (NYSE:DVA) was down 5.8% to $114.16 and Fresenius (NYSE:FMS) was down 9.8% to $32.03.
North Carolina regenerative medicine company Tengion (NSDQ:TNGN) raised $33.6 million in support of clinical studies of its leading programs, the Neo-Kidney Augment and Neo-Urinary Conduit programs. TNGN shares jumped 15.3% to 68¢ around 12:40 p.m. today, up from an opening price of 64¢.